WINNING STRATEGIES WASHINGTON

Lobbying for KALEO · Pharmaceutical development and manufacturing

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Virginia · House · Senate · $20,000.00 income · posted Apr 17, 2026

Lobbying activity 5

Health Issues

Legislation related to prescription drug prices, access to epinephrine in schools, childcare, and other community settings

Pharmacy

Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues

Defense

Medical countermeasures research and development

Budget/Appropriations

Medical countermeasures research and development

Aviation/Airlines/Airports

FAA reauthorization provisions related to emergency medicine.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.